Zevra Therapeutics, Inc.
corporate_fare Company Profile
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for ZVRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ZVRA spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- CHMP Rejects EU Marketing Application for Arimoclomol, EC Decision Due Within 67 Days
- Zevra 10-Q: Q3 Net Income $19.2M, Nine-Month Net Income $65.9M, $270.9M Cash
- Zevra Q3 Revenue Jumps 45% to $37.8M as MIPLYFFA Hits $34M; Swings to $19.2M Profit
- Zevra Q2 Revenue Surges 53% to $39.7M, Beats Consensus; Cash Pile Grows to $260M After Debt Payoff
- Zevra Q2 Revenue Jumps 53% to $39.7M, Crushing Estimates on MIPLYFFA Launch
Financial Snapshot
Short Interest & Short Volume
9.50 days to coverFINRA reported short interest of 6,556,877 shares in ZVRA as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 9.5 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of ZVRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.